Literature DB >> 11285791

BCG immunotherapy for superficial bladder cancer.

C R Lockyer1, D A Gillatt.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11285791      PMCID： PMC1297926          DOI： 10.1177/014107680109400305

Source DB:  PubMed          Journal:  J R Soc Med        ISSN： 0141-0768            Impact factor:   5.344


× No keyword cloud information.
  3 in total

1.  Highly sensitized patients with delayed graft function: a management protocol.

Authors:  D P Hickey; C A Vivas; M L Jordan; W B Lopatin; R Hrebinko; R O'Donovan; T R Hakala
Journal:  J Urol       Date:  1991-01       Impact factor: 7.450

2.  Increased growth of NIH/3T3 cells by transfection with human p120 complementary DNA and inhibition by a p120 antisense construct.

Authors:  L Perlaky; B C Valdez; R K Busch; R G Larson; S M Jhiang; W W Zhang; M Brattain; H Busch
Journal:  Cancer Res       Date:  1992-01-15       Impact factor: 12.701

3.  A low dose bacillus Calmette-Guerin regimen in superficial bladder cancer therapy: is it effective?

Authors:  F Pagano; P Bassi; C Milani; A Meneghini; D Maruzzi; A Garbeglio
Journal:  J Urol       Date:  1991-07       Impact factor: 7.450
  3 in total
  7 in total

1.  Respiratory Homeostasis and Exploitation of the Immune System for Lung Cancer Vaccines.

Authors:  Adam Yagui-Beltrán; Lisa M Coussens; David M Jablons
Journal:  US Oncol       Date:  2009

Review 2.  Germline prognostic markers for urinary bladder cancer: obstacles and opportunities.

Authors:  David W Chang; Jian Gu; Xifeng Wu
Journal:  Urol Oncol       Date:  2012 Jul-Aug       Impact factor: 3.498

3.  Quercetin-induced Growth Inhibition in Human Bladder Cancer Cells Is Associated with an Increase in Ca-activated K Channels.

Authors:  Yangmi Kim; Wun-Jae Kim; Eun-Jong Cha
Journal:  Korean J Physiol Pharmacol       Date:  2011-10-31       Impact factor: 2.016

Review 4.  Prevention and Treatment of Side Effects of Immunotherapy for Bladder Cancer.

Authors:  Kecheng Lou; Shangzhi Feng; Guoxi Zhang; Junrong Zou; Xiaofeng Zou
Journal:  Front Oncol       Date:  2022-05-20       Impact factor: 5.738

5.  Systemic BCG-Osis as a Rare Side Effect of Intravesical BCG Treatment for Superficial Bladder Cancer.

Authors:  S Lukacs; B Tschobotko; N A Szabo; Andrew Symes
Journal:  Case Rep Urol       Date:  2013-06-17

Review 6.  Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.

Authors:  Jedd D Wolchok; F Stephen Hodi; Jeffrey S Weber; James P Allison; Walter J Urba; Caroline Robert; Steven J O'Day; Axel Hoos; Rachel Humphrey; David M Berman; Nils Lonberg; Alan J Korman
Journal:  Ann N Y Acad Sci       Date:  2013-06-17       Impact factor: 5.691

7.  Expression of sialyl-Tn sugar antigen in bladder cancer cells affects response to Bacillus Calmette Guérin (BCG) and to oxidative damage.

Authors:  Paulo F Severino; Mariana Silva; Mylene Carrascal; Nadia Malagolini; Mariella Chiricolo; Giulia Venturi; Annalisa Astolfi; Mariangela Catera; Paula A Videira; Fabio Dall'Olio
Journal:  Oncotarget       Date:  2017-04-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.